CML has a lower mutational burden compared with most solid tumors and, therefore, has a lower number of neoantigens that can be recognized by specific CD8+ CTLs (59), suggesting that LSCs in myeloid leukemia may have a low degree of immunogenicity. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.